» Drug Therapies Post-ACS

Antithrombotic treatment with and without invasive management is a fundamental component of ACS management. While dual antiplatelet therapy (DAPT) combining aspirin and a P2Y12 receptor inhibitor has been consistently shown to reduce recurrent major adverse cardiovascular events in patients with ACS, the combination and time of initiation should reflect the ischaemic and bleeding risk of the patient. Other pharmacological therapies for long term maintenance after an ACS event include high-intensity lipid lowering agents, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers (ARBs) and beta blockers.

Learn more about these drug therapy strategies from Prof. Dr. Kurt Huber. View his presentation from the ACS Forum 2020 webinar and download the accompanying slides for more information. This educational content is relevant for cardiologists, including interventional cardiologists, as well as primary care physicians.

To continue your educational journey, follow the link above to view the complete on-demand video recording of the ACS Forum 2020 webinar. At this link you can also access the accredited e-learning designed around the ACS Forum programme.

The ACS Forum is a medical educational programme supported by an Independent Educational Grant from Amgen.

Prof. Dr Kurt Huber, MD, FESC, FACC, FAHA, is director of the Department of Cardiology and Intensive Care Medicine at the Klinik Ottakring (formerly the Wilhelminen hospital)and Vice Dean of Research and Professor for Acute and Interventional Cardiology at the Sigmund Freud University Medical School, Vienna, Austria. He is an interventional cardiologist with over 35 years of experience. His main research interest covers basic research (mechanisms of thrombus formation and dissolution) as well as clinical research (acute coronary syndromes, organization of STEMI networks, antithrombotic therapy in CV diseases). He has performed over 100 international clinical trials as national coordinator and steering committee member ,has published over800peer reviewed papers, his Hirsh factor is 84 (Thomson Reuters), his lifeIF > 4000, he has organized > 200 national and international conferences, and he has been listed annually from2015-2019among the top0,1% of the most cited researchers globally in ClinicalMedicine.Dr Huber is president of the Austrian Heart Foundation (sinceNovember 2019) and president-elect of the Association of Acute Cardiovascular Care (ACVC) of the EuropeanSociety of Cardiology (ESC )(sinceMarch 2020)

Watch the webinar and take the e-learning: ACS Forum 2020 on demand

Experts

Prof. Gilles Montalescot, Prof. Dr Kurt Huber, Dr Sergio Raposeiras Roubín, Prof. Dr J. Wouter Jukema, Dr Miklos Rohla, Prof. Dr Jean-Philippe Collet, Prof. Dr Ángel Cequier Fillat, Prof. Dr Jeanine Roeters van Lennep, Prof. Dr Uwe Zeymer, Prof. Dr Giovanni Esposito